Mealtime Safety Nets Insulet’s Bolus Dosing Safeguards for Automated Insulin Delivery

Insulet Corporation, the maker of the Omnipod insulin delivery system, has filed a patent for systems and methods that ensure adequate insulin bolus doses are delivered when a person with diabetes eats a meal – providing both safety safeguards and automatic detection and correction mechanisms for a critical aspect of automated insulin delivery management.

The Problem

Automated insulin delivery systems – also known as closed-loop or artificial pancreas systems – represent the most advanced available technology for managing type 1 diabetes and, increasingly, insulin-requiring type 2 diabetes. These systems use continuous glucose monitoring data to automatically adjust insulin delivery in real time, dramatically reducing the burden of manual glucose monitoring and dose calculation for people with diabetes.

However, even highly sophisticated automated systems face a fundamental challenge with meal-related insulin dosing. When a person eats carbohydrates, glucose rises rapidly in the bloodstream, and insulin must be delivered in advance of or simultaneously with eating to prevent dangerous post-meal glucose spikes. While automated systems can detect rising glucose and increase insulin delivery in response, reacting to glucose that is already rising is inherently slower than delivering a pre-emptive mealtime bolus dose.

The consequence of insufficient mealtime insulin dosing – whether because the user forgot to announce a meal, underestimated carbohydrate content, or because the automated system’s reactive response was too slow – is post-prandial hyperglycaemia (high blood sugar after eating). Sustained post-meal glucose spikes are associated with both short-term discomfort and long-term diabetes complications. Conversely, if the automated system delivers too much insulin in response to detected glucose rises without correctly accounting for the meal, hypoglycaemia (dangerously low blood sugar) can result.

What This Invention Does

Insulet’s invention addresses this challenge by building safeguards into the medication delivery algorithm of an automated drug delivery system – specifically designed to prevent or compensate for insufficient bolus doses at mealtimes. The safeguards can work in two ways: by enabling the user to manually confirm or add a mealtime bolus dose, or by the system automatically delivering a bolus dose when a meal is detected.

The system includes methods for detecting when a meal has been ingested – through mechanisms such as detecting patterns in glucose sensor data that are characteristic of meal-related glucose excursions, user-initiated meal announcements, or other indicators of carbohydrate intake. Once a meal is detected or confirmed, the system can ensure that a proper bolus dose is delivered – either prompting the user if they have not already dosed, or automatically administering the required insulin.

The algorithm-based approach means these safeguards are integrated into the core logic of the automated delivery system, not bolted on as a separate function. This integration allows the safeguard functions to interact seamlessly with the system’s ongoing glucose control algorithm, adjusting the approach based on the current glucose level, recent insulin delivery history, and the user’s individual response characteristics.

Key Features

Algorithm-integrated meal safeguards. Safety mechanisms for mealtime bolus dosing are built into the core medication delivery algorithm rather than being separate features, enabling coordinated management of meal detection and insulin delivery.

Dual manual and automatic options. The system supports both manual user-initiated bolus dosing (with appropriate prompts and confirmations) and automatic bolus delivery by the system, providing flexibility for different user preferences and situations.

Meal ingestion detection. The invention includes methods for the system to determine when a meal has been ingested – enabling proactive or reactive safeguard responses without requiring the user to always manually announce eating events.

Insufficient dose prevention and compensation. The safeguards are specifically designed to address the scenario of insufficient bolus delivery – preventing the failure from occurring or compensating for it after detection.

Automated drug delivery platform. The system is implemented in the context of an automated drug delivery device – specifically an insulin pump with integrated closed-loop control – reflecting Insulet’s commercial focus on the Omnipod ecosystem.

Who Is Behind It?

Insulet Corporation is a Massachusetts-based medical device company and the developer of the Omnipod tubeless insulin pump system, which has become one of the most widely used insulin delivery platforms globally. The inventors – Jason O’Connor, Ashutosh Zade, Yibin Zheng, Rangarajan Narayanaswami and Joon Bok Lee – bring deep expertise in closed-loop insulin delivery algorithms, glucose sensing and diabetes management systems. The application is filed through Davies Collison Cave in Melbourne and is a divisional of an earlier filing (AU 2023209422).

Why It Matters

Automated insulin delivery represents the current pinnacle of diabetes technology, and meal management is one of the aspects of diabetes control where even the best systems still fall short. Post-meal glucose spikes are among the most challenging aspects of glucose management, particularly for people whose meals are variable in timing and carbohydrate content, and who cannot always reliably pre-announce every eating event to their device.

Safeguards that ensure adequate mealtime insulin delivery – whether by alerting the user when they appear to have eaten without bolusing, or by automatically compensating for detected insufficient dosing – directly address one of the most common failure modes in automated insulin delivery. For people with diabetes, better mealtime glycaemic control means less time with dangerously high post-meal glucose levels, reduced risk of both short-term complications like diabetic ketoacidosis and long-term complications including cardiovascular disease, kidney disease and neuropathy. Insulet’s investment in this area reflects the company’s understanding that closing the loop on meal management is as important as the basal glucose control that current systems already handle well.

---

AU 2026201621 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.